Chemicalinfo Chemlink Pharm-Chem Net

Abstract

Background. Vatalanib (PTK787/ZK 222584) is an orally active and selective inhibitor of the vascular endothelial growth factor receptor (VEGFR) tyrosine kinases. A phase I/II study examined the safety and response profile of vatalanib in combination with 5-fluorouracil/leucovorin/oxaliplatin (FOLFOX4) in patients with advanced colorectal cancer (CRC).
Patients and Methods. Patients with previously untreated, inoperable, measurable, advanced-stage CRC were administered escalating doses of vatalanib (500-2000 mg/day p.o.) in 42-day cycles. The FOLFOX4 regimen was coadministered with vatalanib, and treatment was continued until disease progression or unacceptable toxicity occurred. Tumor response was assessed every 12 weeks.

Imatinib (Gleevec ®) Imatinib is a drug used to treat certain types of cancer. It is currently marketed by Novartis as Gleevec (USA) or Glivec (Europe/Australia) as its mesylate salt, imatinib mesilate (INN). It is occasionally referred...

Erlotinib (Tarceva®) Erlotinib hydrochloride (trade name Tarceva, Genentech/OSIP, originally coded as OSI-774) is a drug used to treat non-small cell lung cancer, pancreatic cancer and several other types of cancer.Similar to gefitinib, erlo...

The Food and Drug Administration (FDA) has approved Tykerb (lapatinib), a new targeted anti-cancer treatment, to be used in combination with capectabine (Xeloda), another cancer drug, for patients with advanced, metastatic breast cancer that is HER2 positive (tumors that exhibit HER2 protein).